EGFR and neoplasm: Furthermore, combining the oligoclonal antibody with a low dose of a third‐generation inhibitor of EGFR improved anti‐tumor efficacy, avoided recurrence, and durably cleared tumors in mice, features that may justify larger scale tests of 3×mAbs, either alone or in combinations, in clinical settings.